Premium
Prostate cancer characteristics and outcome in renal transplant recipients: results from a contemporary single center study
Author(s) -
Pettenati Caroline,
Jannot AnneSophie,
Hurel Sophie,
Verkarre Virginie,
Kreis Henri,
Housset Martin,
Legendre Christophe,
Méjean Arnaud,
Timsit MarcOlivier
Publication year - 2016
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12773
Subject(s) - medicine , prostatectomy , single center , biochemical recurrence , prostate cancer , transplantation , brachytherapy , incidence (geometry) , urology , surgery , radiation therapy , demographics , retrospective cohort study , cancer , renal transplant , physics , optics , demography , sociology
Background Prostate cancer ( PC a) incidence is expected to increase in renal transplant recipients ( RTR ) with no clear nor contemporary data on management and oncological outcome. Methods We conducted a retrospective single center study of RTR diagnosed with PC a after transplantation between 2000 and 2013. Demographics, PC a characteristics, and treatment were assessed. For each RTR in radical prostatectomy ( RP ) subset, we included 4 non‐organ transplant patients who underwent RP by the same surgeons, and compared pre‐operative and post‐operative oncological features, and biochemical recurrence ( BCR ) rate. Results Twenty‐four RTR were included ( PC a incidence 1.5%). Mean follow‐up was 47 months. PC a was mostly localized (n=21, 87.5%) with treatments including RP (n=16, 76.2%), brachytherapy (n=3, 14.3%), radiation therapy (n=1, 4.7%), and active surveillance (n=1, 4.7%). No graft loss due to PC a treatment was reported. Nineteen RTR with localized PC a (90.5%) were free from BCR . Considering RP subset, no difference in PC a characteristics at diagnosis and BCR rate was found between RTR (n=16) and control patients (n=64). Conclusions Localized PC a following renal transplantation was not associated with adverse features as compared with non‐transplant patients. Standard treatments could be proposed to RTR with satisfying results both on oncological outcome and graft function.